Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma

The rapid development and remarkable success of checkpoint inhibitors have provided significant breakthroughs in cancer treatment, including hepatocellular carcinoma (HCC). However, only 15-20% of HCC patients can benefit from checkpoint inhibitors. Cancer stem cells (CSCs) are responsible for recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Xiaomeng, Guo, Yixuan, Hu, Yan, Bao, Xuanwen, Zhu, Xudong, Fu, Qihan, Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Zheng, Yi, Zhao, Peng, Fang, Weijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847682/
https://www.ncbi.nlm.nih.gov/pubmed/33537099
http://dx.doi.org/10.7150/thno.54648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847682/
https://www.ncbi.nlm.nih.gov/pubmed/33537099
http://dx.doi.org/10.7150/thno.54648

Ejemplares similares